Get notified when TEVA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTeva announces acquisition of Emalex Biosciences and reports Q1 2026 earnings
Filed April 29, 2026 · Period ending April 29, 2026 · ~1 min read
Key Changes
-
high
Teva entered into a definitive agreement to acquire Emalex Biosciences, a deal announced April 29, 2026. Financial terms and strategic rationale were not disclosed in the 8-K filing itself.
Item 8.01 view on EDGAR → -
high
Teva reported first quarter 2026 financial results via press release on April 29, 2026. The 8-K references the earnings report as an exhibit but does not include actual financial figures or performance metrics.
Item 2.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade TEVA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 2, 2026 4:24 PM